Insulin resistance is increased by transdermal estrogen therapy in postmenopausal women with cardiac syndrome X

A. R. Assali, Z. Jabara, Z. Shafer, A. Solodky, I. Herz, E. Sclarovsky, B. Strasberg, S. Sclarovsky, M. Fainaru

Research output: Contribution to journalArticlepeer-review

Abstract

Estrogen has been reported to have both short- and long-term effects on the cardiovascular system. However, it remains to be examined how short-term transdermal estrogen therapy (TET) affects insulin sensitivity (SI) in patients with cardiac syndrome X (CSX), who are characterized by elevated insulin resistance. SI was assessed in a randomized, double-blind, placebo-controlled crossover study by minimal model analysis in seven postmenopausal women with CSX treated by TET. SI decreased by 32 ± 8.3%, from 5.94 ± 1.14 at baseline to 3.61 ± 0.40 [(10-4 × min-1)/(μU/ml)] during TET (p = 0.03). Time to the onset of symptoms increased from 414.2 ± 51.0 s at baseline to 450.0 ± 53.2 s (p = 0.04). We conclude that TET increases SI in postmenopausal women with CSX. This effect is unrelated to the beneficial anti-ischemic effects on exercise duration.

Original languageEnglish
Pages (from-to)31-34
Number of pages4
JournalCardiology
Volume95
Issue number1
DOIs
StatePublished - 2001

Keywords

  • Cardiac syndrome X
  • Estrogen replacement therapy
  • Insulin resistance

Fingerprint

Dive into the research topics of 'Insulin resistance is increased by transdermal estrogen therapy in postmenopausal women with cardiac syndrome X'. Together they form a unique fingerprint.

Cite this